The chart is not accessible to screen readers. Please switch to the table view to access the data.
Advertisement
Advertisement
M&A deals in the cell and gene therapy sector from 2017 to 2019 (in million U.S. dollars)
M&A deal value in the cell and gene therapy sector 2017-2019
This statistic shows the merger and aquisition (M&A) deals in the cell and gene therapy sector from 2017 to 2019. In 2019, these M&A deals totaled to a value of 11.28 billion U.S. dollars, compared to 18.94 billion U.S. dollars in 2018.
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Statistics on
About the industry
10
- Basic Statistic Major partnerships in the cell and gene therapy industry in 2021, by upfront payment
- Basic Statistic Cell and gene therapy top major venture financings in 2021
- Basic Statistic Global ongoing regenerative medicine clinical trials by phase and sponsor Q2 2024
- Premium Statistic Global cell and gene therapy pipeline by phase 2016
- Premium Statistic Stem cell market - research priorities of companies
- Basic Statistic Regenerative medicines market share by application forecast 2016 and 2025
- Basic Statistic Regenerative medicines market size by therapy type forecast 2016-2025
- Basic Statistic Regenerative medicines market size forecast 2025
- Basic Statistic U.S. and Europe's selected anti-CD19 Car-T therapy sales forecast 2024
- Premium Statistic Top companies based on CAR-T cancer therapy patents 2010-2021
About the region
10
- Basic Statistic Leading respiratory deals by biopharma companies worldwide in 2020, by value
- Premium Statistic ATMP clinical trials share globally by type of sponsor 2016
- Premium Statistic ATMP clinical trials non-commercial sponsors distribution globally 2016
- Premium Statistic ATMP trials classification share by disease and development phase globally 2016
- Basic Statistic Number of acquisition deals in biopharma industry 2017-2021, by therapy focus
- Premium Statistic Number of gene, cell, and RNA therapy deals quarterly 2025, by type
- Premium Statistic CRISPR-Cas gene market size projections globally 2023 vs 2033
- Premium Statistic CRISPR gene editing market share projections by world region 2019 vs 2030
- Premium Statistic Gene, cell, and RNA therapy startup financing quarterly Q4 2021-Q4 2025
- Premium Statistic CRISPR gene editing market share globally by application 2020-2031
Selected statistics
10
- Premium Statistic Capital raised by regenerative medicine companies worldwide 2016-2023
- Basic Statistic Regenerative medicine companies by world region Q3 2025
- Basic Statistic Number of CAR cell therapy trials U.S. vs China 2009-2016
- Basic Statistic Number of CAR cell therapy trials worldwide 2007-2016
- Premium Statistic Global stem cell therapy market size forecast 2022-2032
- Premium Statistic Global cell and gene therapy manufacturing market forecast 2023-2034
- Premium Statistic Global stem cell market size by world region 2011-2016
- Premium Statistic Stem cell technologies and applications market share by world region 2016
- Basic Statistic Global cell culture market size 2022-2030
- Basic Statistic Venture capital funding for companies in CAR-T programs 2011-2016
Other regions
10
- Basic Statistic Number of U.S. biopharma M&A deals 2015-2019, by transaction volume
- Premium Statistic Number of HSC transplants in the US from 2010-2015
- Premium Statistic Hospital charges for an HSC transplant in the U.S. in 2014, by procedure
- Basic Statistic Number of HSC transplants in the US from 2010-2016, by condition and source
- Basic Statistic Medicare charges and costs for an HSC transplant in 2014, by procedure
- Premium Statistic Hospital costs for an HSC transplant in the U.S. in 2014, by procedure
- Basic Statistic US and European VC-backed oncology biopharma company M&A values 2010-2019
- Premium Statistic Leading pharmaceutical M&A deal value in China 2019, by acquirer
- Basic Statistic Number of M&A healthcare deals in California and the U.S. in 2021, by sector
- Premium Statistic Swiss biotech companies: R & D expenses 2016-2025
Related statistics
10
- Premium Statistic Value of investments made in ToolGen South Korea 2000-2018
- Premium Statistic Operating profit Bioneer Corporation 2015-2024
- Basic Statistic Total value of private biopharma M&A deals worldwide 2008-2012
- Basic Statistic Share of biopharma M&A deals worldwide with upfront payment 2017-21, by therapy area
- Basic Statistic Combined value of biopharma takeout deals worldwide 2017-2021, by therapy focus
- Premium Statistic Gross profit Bioneer Corporation 2015-2024
- Premium Statistic Operating profit ToolGen 2014-2024
- Premium Statistic Net profit of ToolGen 2014-2024
- Premium Statistic Total number of pharma merger and acquisition deals 2020-2024
- Premium Statistic Value of pharma and biotech merger and acquisition deals 2020-2024
Further Content: You might find this interesting as well
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Alliance for Regenerative Medicine. (January 7, 2020). M&A deals in the cell and gene therapy sector from 2017 to 2019 (in million U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 29, 2026, from /statistics/1088730/manda-deal-value-in-the-cell-and-gene-therapy-sector/
Alliance for Regenerative Medicine. "M&A deals in the cell and gene therapy sector from 2017 to 2019 (in million U.S. dollars)." Chart. January 7, 2020. ÌÇÐÄÆƽâ°æ. Accessed July 29, 2026. /statistics/1088730/manda-deal-value-in-the-cell-and-gene-therapy-sector/
Alliance for Regenerative Medicine. (2020). M&A deals in the cell and gene therapy sector from 2017 to 2019 (in million U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 29, 2026. /statistics/1088730/manda-deal-value-in-the-cell-and-gene-therapy-sector/
Alliance for Regenerative Medicine. "M&a Deals in The Cell and Gene Therapy Sector from 2017 to 2019 (in Million U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 7 Jan 2020, /statistics/1088730/manda-deal-value-in-the-cell-and-gene-therapy-sector/
Alliance for Regenerative Medicine, M&A deals in the cell and gene therapy sector from 2017 to 2019 (in million U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/1088730/manda-deal-value-in-the-cell-and-gene-therapy-sector/ (last visited July 29, 2026)
M&A deals in the cell and gene therapy sector from 2017 to 2019 (in million U.S. dollars) [Graph], Alliance for Regenerative Medicine, January 7, 2020. [Online]. Available: /statistics/1088730/manda-deal-value-in-the-cell-and-gene-therapy-sector/
Advertisement